Key Drivers
- Strong Liquidity
- Cash Burn
- Rich Valuation
AIAI Summary
RLAY is no longer just a cash-burn story because its triplet oncology program now offers a clearer late-stage catalyst path, but investors should treat it as a high-optional, high-dilution biotech until Phase 3 timing, regulatory feedback, and clinical durability prove the thesis can convert strong cash runway into real value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Cash Burn
- •Rich Valuation
RLAY's balance sheet is exceptionally strong with ample cash and low debt, but persistent large losses, negative free cash flow, and very rich revenue multiples keep the investment case risky.
Price Behavior
Key Price Behavior Insights:
- •Upper-half range
- •Resistance capped
- •Support holding
Over the last month, RLAY has traded range-bound around $19.86, recovering from a $18.29 low but still capped by $20.00-$20.10 resistance, making the setup neutral to mildly positive unless it breaks above $20.10 or slips below $18.80.
Touched $20.07 then pulled back, leaving the breakout unconfirmed
Sentiment & News
Key News Insights:
- •Q2 Miss
- •Triplet Selected
- •Phase 3 Path
Relay Therapeutics missed Q2 expectations but continues advancing its oncology pipeline, with zovegalisib plus atirmociclib selected for first-line breast cancer and a Phase 3 study targeted for early 2027.
The earnings miss may weigh on near-term sentiment, but ongoing clinical progress helps preserve long-term upside potential
Similar Companies in Healthcare
Other companies in the same sector with AI ratings